Reich, Kristian, Eric Simpson, Richard Langley, Richard Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein De Bruin Weller, and Andrew Blauvelt. 2023. “Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate to Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine 7 (2):s143. https://doi.org/10.25251/skin.7.supp.143.